Skip to content
lifestyle.the-newshub.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
VANDA PHARMACEUTICALS INC
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
May 31, 2026
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
May 28, 2026
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
May 28, 2026
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
May 27, 2026
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
May 27, 2026
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
May 27, 2026
Vanda Pharmaceuticals announces the publication of “Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis” in NEJM Evidence
May 26, 2026
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
May 26, 2026
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
May 23, 2026
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
May 23, 2026
1
2
3
Next Page
→